journal article·2022-03

Transcutaneous tumor vaccination combined with anti-programmed death-1 monoclonal antibody treatment produces a synergistic antitumor effect

Xinran Song, Yuxin Jiang, Weixing Zhang, Gomaa Elfawal, Kaili Wang, Di Jiang, Huoyan Hong, Jinglei Wu, Chuanglong He, Xiumei Mo, Hongsheng Wang

Acta Biomaterialia· Volume 140
Publisher page

Abstract

Transcutaneous immunization (TCI) has the advantages of safety, high efficiency, non-invasiveness and convenient use. The key for a TCI system is transdermal targeted delivery of antigen to dendritic cells (DCs), the most powerful antigen presenting cells. DCs also play an important role in tumor immunotherapy, which provides a huge imagination for the application of TCI to tumor treatment. In this study, a transcutaneous tumor vaccine (TTV) delivery system was developed using the electrospun silk fibroin (SF) and polyvinyl alcohol (PVA) composite nanofibrous patch loaded with mannosylated polyethyleneimine (PEIman)-modified ethosome (Eth) (termed Eth-PEIman). Eth-PEIman showed a good performance in targeting DCs, and the carriers loaded with antigen (encapsulated in Eths) and adjuvant (absorbed in PEIman) were observed effectively induce DCs maturation in vitro. With the tyrosinase-related protein-2 (TRP2) peptide as antigen and oligodeoxynucleotides containing unmethylated CpG motifs as adjuvant, the TTV-loaded patches (TTVP) significantly inhibited the growth of melanoma in a syngeneic mouse model for melanoma by subcutaneous injection of B16F10 cell lines. Moreover, the combined application of the TTVP and anti-programmed death-1 monoclonal antibody (aPD-1) produced a synergistic antitumor effect, which could be related to the infiltration of more CD4+ and CD8+ T cells in the tumor tissues. The application of TTVP also increased the expression of IL-12, which may be part of the mechanism of synergistic antitumor effect between the TTVP and aPD-1. These results suggest that the combination of the TTVP and immune checkpoint blockers could be an effective strategy for tumor treatment. STATEMENT OF SIGNIFICANCE: Transcutaneous immunization has the advantages of safety, high efficiency, non-invasiveness and convenient use. In this study, a novel transcutaneous tumor vaccine patch (TTVP) was developed using tumor antigens-loaded ethosomes that can target dendritic cells percutaneously. Our data demonstrated that the TTVP can significantly inhibit tumor growth. Furthermore, the combination of TTVP and aPD-1 produced a synergistic anti-melanoma effect. Considering its convenience and non-invasiveness, this TTVP system could find good application prospects in immunotherapy. The combination of TTVP and aPD-1 could be a useful strategy for the prevention and treatment of tumors.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Immunotherapy and Immune Responses · RNA Interference and Gene Delivery · CAR-T cell therapy research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (66)

Show source-provided references
1. Decisions about dendritic cells: past, present, and future10.1146/annurev-immunol-100311-102839 ↗
2. Interleukin-6 induced "acute" phenotypic microenvironment promotes Th1 anti-tumor immunity in cryo-thermal therapy revealed by shotgun and parallel reaction monitoring proteomics10.7150/thno.14394 ↗
3. Improved genetic immunization via micromechanical disruption of skin-barrier function and targeted epidermal delivery10.1038/nm0402-415 ↗
4. Transcutaneous immunization: an emerging route of immunization and potent immunostimulation strategy10.1615/CritRevTherDrugCarrierSyst.v18.i5.30 ↗
5. Review of transcutaneous and intradermal vaccination10.4161/hv.7.8.16274 ↗
6. Overcoming or circumventing the stratum corneum barrier for efficient transcutaneous immunization10.1016/j.drudis.2017.09.017 ↗
7. Nanovesicular carriers as alternative drug delivery systems: ethosomes in focus10.1517/17425247.2013.860130 ↗
8. In vitro assessment of pharmaceutical potential of ethosomes entrapped with terbinafine hydrochloride10.1016/j.jare.2016.03.003 ↗
9. CD44 Assists the topical anti-psoriatic efficacy of curcumin-loaded hyaluronan-modified ethosomes: a new strategy for clustering drug in inflammatory skin10.7150/thno.29715 ↗
10. Design, characterization and comparison of transdermal delivery of colchicine via borneol-chemically-modified and borneol-physically-modified ethosome10.1080/10717544.2018.1559258 ↗
11. Enhanced transdermal bioavailability of testosterone propionate via surfactant-modified ethosomes10.2147/IJN.S46748 ↗
12. Polyethylenimine and sodium cholate-modified ethosomes complex as multidrug carrier for the treatment of melanoma through transdermal delivery10.2217/nnm-2018-0398 ↗
13. Galactosylated chitosan-modified ethosomes combined with silk fibroin nanofibers is useful in transcutaneous immunization10.1016/j.jconrel.2020.07.047 ↗
14. Dressed for success’ C-type lectin receptors for the delivery of glyco-vaccines to dendritic cells10.1016/j.coi.2010.11.011 ↗
15. Enhancement of immune responses by DNA vaccination through targeted gene delivery using mannosylated cationic liposome formuLations following intravenous administration in mice10.1016/j.bbrc.2004.03.141 ↗
16. Comparative binding and uptake of liposomes decorated with mannose oligosaccharides by cells expressing the mannose receptor or dc-sign10.1016/j.carres.2019.107877 ↗
17. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation10.1084/jem.184.2.747 ↗
18. CPG loaded MoS(2) nanosheets as multifunctional agents for photothermal enhanced cancer immunotherapy10.1039/C7NR01460K ↗
19. Clinical evaluation of CPG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer10.1016/j.vaccine.2014.06.065 ↗
20. Nanoscale zeolitic imidazolate framework-8 as efficient vehicles for enhanced delivery of CPG oligodeoxynucleotides10.1021/acsami.7b09583 ↗
21. Inflammation-triggered cancer immunotherapy by programmed delivery of CPG and anti-PD1 antibody10.1002/adma.201506312 ↗
22. Therapeutic potential of toll-like receptor 9 activation10.1038/nrd2059 ↗
23. DEC-205 is a cell surface receptor for CPG oligonucleotides10.1073/pnas.1208796109 ↗
24. Nanodelivery systems for enhancing the immunostimulatory effect of cpg oligodeoxynucleotides10.1016/j.msec.2016.03.045 ↗
25. Investigation of dendritic mesoporous silica nanoparticles for cytosine-phosphate-guanosine oligodeoxynucleotide delivery10.1166/mex.2016.1288 ↗
26. Current status of polymeric gene delivery systems10.1016/j.addr.2006.03.007 ↗
27. Polyethylenimine: a versatile, multifunctional non-viral vector for nucleic acid delivery10.1016/j.msec.2016.07.066 ↗
28. A biodegradable low molecular weight polyethylenimine derivative as low toxicity and efficient gene vector10.1021/bc800428y ↗
29. Polyethylenimine-mediated CPG oligodeoxynucleotide delivery stimulates bifurcated cytokine induction10.1021/acsbiomaterials.8b00049 ↗
30. Synthesis of mannosylated polyethylenimine and its potential application as cell-targeting non-viral vector for gene therapy10.3390/polym6102573 ↗
31. A mannosylated cell-penetrating peptide-graft-polyethylenimine as a gene delivery vector10.1016/j.biomaterials.2014.01.065 ↗
32. A mannosylated pei-cpp hybrid for trail gene targeting delivery for colorectal cancer therapy10.1039/C7PY00882A ↗
33. Benzoyl peroxide microsphere formulations: what is the science supporting microsphere vehicle technology and clinical use?
34. Fabrication and properties of superhydrophobic waterborne polyurethane composites with micro-rough surface structure using electrostatic spraying
35. Nanofiber technology: designing the next generation of tissue engineering scaffolds10.1016/j.addr.2007.04.022 ↗
36. Green electrospun Manuka honey/silk fibroin fibrous matrices as potential wound dressing10.1016/j.matdes.2017.01.023 ↗
37. Silk fibroin-Pellethane® cardiovascular patches: effect of silk fibroin concentration on vascular remodeling in rat model10.1007/s10856-017-5999-z ↗
38. Estradiol-loaded poly(ε-caprolactone)/silk fibroin electrospun microfibers decrease osteoclast activity and retain osteoblast function10.1021/acsami.8b01855 ↗
39. 3-D mineralized silk fibroin/polycaprolactone composite scaffold modified with polyglutamate conjugated with BMP-2 peptide for bone tissue engineering10.1016/j.colsurfb.2017.12.043 ↗
40. Starch nanoparticle as a vitamin E-TPGS carrier loaded in silk fibroin-poly(vinyl alcohol)-Aloe vera nanofibrous dressing10.1016/j.colsurfb.2018.03.004 ↗
41. Nanofibrous nonmulberry silk/PVA scaffold for osteoinduction and osseointegration10.1002/bip.22594 ↗
42. Bactericidal and antifouling electrospun PVA nanofibers modified with a quaternary ammonium salt and zwitterionic sulfopropylbetaine10.1016/j.msec.2020.110855 ↗
43. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer10.1056/NEJMoa1200690 ↗
44. Advances in targeting cell surface signalling molecules for immune modulation. Nature reviews10.1038/nrd3877 ↗
45. Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma - results of a prospective biomarker study10.1186/s40425-019-0659-0 ↗
46. Understanding genetic determinants of resistance to immune checkpoint blockers10.1016/j.semcancer.2019.12.020 ↗
47. Sting agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade10.1126/scitranslmed.aaa4306 ↗
48. Targeting TMEM176B enhances antitumor immunity and augments the efficacy of immune checkpoint blockers by unleashing inflammasome activation10.1016/j.ccell.2019.04.003 ↗
49. Intratumoral expression of IL-7 and IL-12 using an oncolytic virus increases systemic sensitivity to immune checkpoint blockade
50. Immune checkpoint blockade and its combination therapy with small-molecule inhibitors for cancer treatment10.1016/j.bbcan.2018.12.002 ↗
51. Strategies of combination drug delivery for immune checkpoint blockades10.1002/adhm.201801099 ↗
52. Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving thecytokines IFN-γ and IL-1210.1016/j.immuni.2018.09.024 ↗
53. Dendritic cell activation by an E. coli-derived monophosphoryl lipid A enhances the efficacy of PD-1 blockade10.1016/j.canlet.2019.12.012 ↗
54. Functionalized selenium nanoparticles for targeted siRNA delivery silence Derlin1 and promote antitumor efficacy against cervical cancer10.1080/10717544.2019.1667452 ↗
55. Folate-modified chitosan nanoparticles containing the IP-10 gene enhance melanoma-specific cytotoxic CD8(+)CD28(+) T lymphocyte responses10.7150/thno.14527 ↗
56. Co-delivery of tumor antigen and dual toll-like receptor ligands into dendritic cell by silicon microparticle enables efficient immunotherapy against melanoma10.1016/j.jconrel.2018.01.004 ↗
57. The enhanced antitumor-specific immune response with mannose- and CPG-ODN-coated liposomes delivering Trp2 peptide10.7150/thno.22056 ↗
58. Trp2 peptide vaccine adjuvanted with (R)-DOTAP inhibits tumor growth in an advanced melanoma model10.1021/mp200350n ↗
59. Cationic micelle delivery of Trp2 peptide for efficient lymphatic draining and enhanced cytotoxic T-lymphocyte responses10.1016/j.jconrel.2014.12.024 ↗
60. Nanoparticles and nanofibers for topical drug delivery10.1016/j.jconrel.2015.10.049 ↗
61. Influence of PVP/VA copolymer composition on drug-polymer solubility10.1016/j.ejps.2016.01.026 ↗
62. In vivo delivery of peptides and Toll-like receptor ligands by mannose-functionalized polymeric nanoparticles induces prophylactic and therapeutic anti-tumor immune responses in a melanoma model10.1016/j.jconrel.2014.11.033 ↗
63. Tumor-targeted delivery of sunitinib base enhances vaccine therapy for advanced melanoma by remodeling the tumor microenvironment10.1016/j.jconrel.2016.11.013 ↗
64. A melanin-mediated cancer immunotherapy patch10.1126/sciimmunol.aan5692 ↗
65. The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape10.1007/s00262-004-0517-9 ↗
66. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival10.1038/nm.2883 ↗